Pharmaceutical

NorthStar and Convergent expand deal for prostate cancer drug

NorthStar Medical Radioisotopes and Convergent Therapeutics have announced an expanded strategic collaboration for CONV01-α.

Aug 15, 2024 - 04:00
NorthStar and Convergent expand deal for prostate cancer drug
NorthStar Medical Radioisotopes and Convergent Therapeutics have announced an expanded strategic collaboration for CONV01-α.
Read the original article

Tags:

Previous Article

Diabesity: Overlapping pathophysiology informs multi-indication treatment

Next Article

UAE approves BioArctic and Eisai’s Leqembi for Alzheimer’s disease

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

EC conditionally approves Pfizer’s haemophilia B gene therapy

EC conditionally approves Pfizer’s haemophilia B gene t...

Jul 28, 2024

Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence

Biogen completes $1.15bn HI-Bio acquisition to expand i...

Jul 4, 2024

UK clinical trial sector must address prolonged timelines, say experts

UK clinical trial sector must address prolonged timelin...

Jun 12, 2024